PB 93 of 2025
National Health (Minimum Stockholding) Amendment Determination (No. 7) 2025
I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following determination.
Dated 29 July 2025
Rebecca Richardson
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
1 Name
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments commencing 1 August 2025
National Health (Minimum Stockholding) Determination 2023
Schedule 2—Amendments commencing immediately after the commencement of Schedule 2 to the National Health (Minimum Stockholding) Amendment Determination (No. 2) 2025 – 1 August 2025
National Health (Minimum Stockholding) Determination 2023
Schedule 3—Amendments commencing immediately after the commencement of Schedule 2 to the National Health (Minimum Stockholding) Amendment Determination (No. 4) 2025 – 1 October 2025
National Health (Minimum Stockholding) Determination 2023
(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 7) 2025.
(2) This instrument may also be cited as PB 93 of 2025.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 August 2025. | 1 August 2025 |
2. Schedule 1 | 1 August 2025. | 1 August 2025 |
3. Schedule 2 | Immediately after the commencement of Schedule 2 to the National Health (Minimum Stockholding) Amendment Determination (No. 2) 2025. | 1 August 2025 |
4. Schedule 3 | Immediately after the commencement of Schedule 2 to the National Health (Minimum Stockholding) Amendment Determination (No. 4) 2025. | 1 October 2025 |
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
1 Schedule 1 (table)
Before:
Acarbose | Tablet 100 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |
insert:
Abacavir with lamivudine | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | Oral | Kivexa | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
2 Schedule 1 (table)
After:
Allopurinol | Tablet 100 mg | Oral | APO-ALLOPURINOL | 4 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together |
insert:
Allopurinol | Tablet 100 mg | Oral | NOUMED ALLOPURINOL | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
3 Schedule 1 (table)
After:
Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | 4.5 months stock by reference to usual demand |
insert:
Amlodipine | Tablet 10 mg (as besilate) | Oral | NOUMED AMLODIPINE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
4 Schedule 1 (table)
After:
Amlodipine | Tablet 5 mg (as besilate) | Oral | APX-AMLODIPINE | 6 months stock by reference to usual demand of both Amlodipine APOTEX and APX-AMLODIPINE added together |
insert:
Amlodipine | Tablet 5 mg (as besilate) | Oral | NOUMED AMLODIPINE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
Amoxicillin | Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | Oral | NOUMED AMOXICILLIN | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
5 Schedule 1 (table)
Omit:
Arsenic | Injection concentrate containing arsenic trioxide 10 mg in 10 mL | Injection | Arsenic Trioxide-AFT | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
6 Schedule 1 (table)
Omit:
Bivalirudin | Powder for I.V. injection 250 mg (as trifluoroacetate) | Injection | Bivalirudin APOTEX | 4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together |
7 Schedule 1 (table)
After:
Captopril | Oral solution 5 mg per mL, 95 mL | Oral | Capoten | 4 months stock by reference to usual PBS demand |
insert:
Cefalexin | Capsule 500 mg (as monohydrate) | Oral | NOUMED CEFALEXIN | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
8 Schedule 1 (table)
After:
Fentanyl | Transdermal patch 10.20 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 12.375 mg | Transdermal | Fenpatch 75 | between 1 August 2025 and 31 August 2025—0 months stock by reference to usual demand |
9 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 12.6 mg | Transdermal | Durogesic 75 | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
10 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 16.8 mg | Transdermal | Durogesic 100 | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
11 Schedule 1 (table)
After:
Fentanyl | Transdermal patch 16.8 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 2.063 mg | Transdermal | Fenpatch 12 | between 1 August 2025 and 31 August 2025—0 months stock by reference to usual demand |
12 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 2.1 mg | Transdermal | Durogesic 12 | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
13 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 4.2 mg | Transdermal | Durogesic 25 | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
14 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 8.4 mg | Transdermal | Durogesic 50 | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
15 Schedule 1 (table)
Omit:
Fluorouracil | Injection 5000 mg in 100 mL | Injection | Fluorouracil Ebewe | between 1 July 2025 to 31 July 2025—0 months stock by reference to usual demand |
16 Schedule 1 (table)
Omit:
Glimepiride | Tablet 1 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
17 Schedule 1 (table)
Omit:
Glimepiride | Tablet 2 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
18 Schedule 1 (table)
Omit:
Glimepiride | Tablet 3 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
19 Schedule 1 (table)
Omit:
Glimepiride | Tablet 4 mg | Oral | Glimepiride APOTEX | 6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together |
20 Schedule 1 (table)
Omit:
Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Sublingual | Nitrolingual Pumpspray | (a) between 1 April 2025 and 30 September 2025—162,432 packs of a pack quantity of 1 (b) after 30 September 2025—6 months stock by reference to usual PBS demand |
substitute:
Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Sublingual | Nitrolingual Pumpspray | (a) between 1 August 2025 and 30 September 2025—108,288 packs of a pack quantity of 1 (b) between 1 October 2025 and 31 March 2026—109,488 packs of a pack quantity of 1 (c) after 31 March 2026—4 months stock by reference to usual PBS demand |
21 Schedule 1 (table)
Omit:
Granisetron | Concentrated injection 3 mg (as hydrochloride) in 3 mL | Injection | Granisetron-AFT | between 1 July 2025 to 31 July 2025—0 months stock by reference to usual demand |
22 Schedule 1 (table)
Omit:
Letrozole | Tablet 2.5 mg | Oral | Letrozole APOTEX | 4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together |
23 Schedule 1 (table)
After:
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APX-PANTOPRAZOLE | 6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together |
insert:
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | NOUMED PANTOPRAZOLE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
24 Schedule 1 (table)
After:
Risedronic acid | Tablet containing risedronate sodium 150 mg | Oral | APO‑Risedronate | 3 months stock by reference to usual demand |
insert:
Risperidone | Tablet 0.5 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 November 2025—0 months stock by reference to usual demand |
Risperidone | Tablet 1 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
Risperidone | Tablet 2 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
25 Schedule 1 (table)
After:
Risperidone | Tablet 3 mg | Oral | APO‑Risperidone | 3.5 months stock by reference to usual demand |
insert:
Risperidone | Tablet 3 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
26 Schedule 1 (table)
After:
Risperidone | Tablet 3 mg | Oral | Rispa | 3 months stock by reference to usual demand |
insert:
Risperidone | Tablet 4 mg | Oral | NOUMED RISPERIDONE | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
27 Schedule 1 (table)
Omit:
Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | Sevelamer Apotex | 4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together |
28 Schedule 1 (table)
After:
Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | TENOFOVIR/EMTRICITABINE 300/200 ARX | 3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together |
insert:
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Lamisil (Novartis Pharmaceuticals Australia Pty Limited) | between 1 August 2025 and 31 January 2026—0 months stock by reference to usual demand |
1 Schedule 1 (table)
After:
Ciprofloxacin | Ear drops 3 mg (as hydrochloride) per mL, 5 mL | Application to the Ear | Ciloxan | 6 months stock by reference to usual PBS demand |
insert:
Ciprofloxacin | Tablet 500 mg (as hydrochloride) | Oral | NOUMED CIPROFLOXACIN | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
Ciprofloxacin | Tablet 750 mg (as hydrochloride) | Oral | NOUMED CIPROFLOXACIN | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | NOUMED CITALOPRAM | between 1 August 2025 and 30 September 2025—0 months stock by reference to usual demand |
1 Schedule 1 (table)
Omit:
Triglycerides, long chain with glucose polymer | Oral liquid 1 L, 6 (ProZero) | Oral | ProZero | 6 months stock by reference to usual PBS demand |
substitute:
Triglycerides, long chain with glucose polymer | Oral liquid 1 L, 6 (ProZero) | Oral | ProZero | 0 months stock by reference to usual PBS demand |